Last reviewed 2026-04-20 · How we verify

mycophenolate acid

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Oedema peripheral
• Urinary tract infection
• Diarrhoea
• Hypertension
• Constipation
• Anaemia
• Nausea
• Hyperkalaemia
• Hypophosphataemia
• Proteinuria
• Hypokalaemia
• Blood creatinine increased

Key clinical trials

• Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
• Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (PHASE2)
• A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
• MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases (PHASE2)
• Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
• Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (PHASE2)
• Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation (PHASE2)
• A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• mycophenolate acid CI brief — competitive landscape report
• mycophenolate acid updates RSS · CI watch RSS
• National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI